

REFERENCES

1. Torres-Jimenez, A. R., Ramirez-Nova, V., Cespedes-Cruz, A. I., Sanchez-Jara, B., Velazquez-Cruz, A., Bekker-Méndez, V. C., & Guerra-Castillo, F. X. (2022). Primary antiphospholipid syndrome in pediatrics: beyond thrombosis. Report of 32 cases and review of the evidence. *Pediatric rheumatology online journal*, 20(1), 13. <https://doi.org/10.1186/s12969-022-00673-y>
2. Madison, J. A., Zuo, Y., & Knight, J. S. (2020). Pediatric antiphospholipid syndrome. *European journal of rheumatology*, 7(Suppl1), S3–S12. <https://doi.org/10.5152/eurjrheum.2019.19160>
3. Kopytek, M., Natorska, J., & Undas, A. (2018). Antiphosphatidylserine/prothrombin (aPS/PT) antibodies are associated with Raynaud phenomenon and migraine in primary thrombotic antiphospholipid syndrome. *Lupus*, 27(5), 812–819. <https://doi.org/10.1177/0961203317751644>
4. García-Carrasco, M., Mendoza-Pinto, C., Jiménez-Hernández, C., et al. (2013). *Antiphospholipid syndrome*. Dalam J. M. Anaya, Y. Shoenfeld, A. Rojas-Villarraga, et al. (Ed.), *Autoimmunity: From bench to bedside* (Bab 26). El Rosario University Press. <https://www.ncbi.nlm.nih.gov/books/NBK459442/>
5. Barbhaiya, M., Zuily, S., Naden, R., Hendry, A., Manneville, F., Amigo, M. C., Amoura, Z., Andrade, D., Andreoli, L., Artim-Esen, B., Atsumi, T., Avcin, T., Belmont, H. M., Bertolaccini, M. L., Branch, D. W., Carvalheiras, G., Casini, A., Cervera, R., Cohen, H., Costedoat-Chalumeau, N., ... ACR/EULAR APS Classification Criteria Collaborators (2023). The 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria. *Arthritis & rheumatology (Hoboken, N.J.)*, 75(10), 1687–1702. <https://doi.org/10.1002/art.42624>
6. Islabão, A. G., Trindade, V. C., da Mota, L. M. H., Andrade, D. C. O., & Silva, C. A. (2022). Managing Antiphospholipid Syndrome in Children and Adolescents: Current and Future Prospects. *Paediatric drugs*, 24(1), 13–27. <https://doi.org/10.1007/s40272-021-00484-w>
7. Kobza, A. O., Herman, D., Papaioannou, A., Lau, A. N., & Adachi, J. D. (2021). Understanding and Managing Corticosteroid-Induced Osteoporosis. *Open access rheumatology : research and reviews*, 13, 177–190. <https://doi.org/10.2147/OARRR.S282606>
8. Torres-Jimenez, A. R., Ramirez-Nova, V., Cespedes-Cruz, A. I., Sanchez-Jara, B., Velazquez-Cruz, A., Bekker-Méndez, V. C., & Guerra-Castillo, F. X. (2022). Primary antiphospholipid syndrome in pediatrics: beyond thrombosis. Report of 32 cases and review of the evidence. *Pediatric rheumatology online journal*, 20(1), 13. <https://doi.org/10.1186/s12969-022-00673-y>
9. Islabão, A. G., Trindade, V. C., da Mota, L. M. H., Andrade, D. C. O., & Silva, C. A. (2022). Managing Antiphospholipid Syndrome in Children and Adolescents: Current and Future Prospects. *Paediatric drugs*, 24(1), 13–27. <https://doi.org/10.1007/s40272-021-00484-w>



10. Essouma, M., Nkeck, J.R. and Noubiap, J.J. (2024) 'Epidemiology of thromboembolic events in children and adolescents with antiphospholipid syndrome: A systematic review with meta-analysis', *Reumatologia Clínica*, 20, pp. 155–161. <https://doi.org/10.1016/j.reuma.2023.10.001>
11. Islam, M. A., Ahmed, S., Sultana, S., Alam, S. S., Hossan, T., Gouda, W., Alsaqabi, F., Hassan, R., & Kotyla, P. J. (2024). Vitamin D Status in Patients with Primary Antiphospholipid Syndrome (PAPS): A Systematic Review and Meta-Analysis. *Antibodies (Basel, Switzerland)*, 13(1), 22. <https://doi.org/10.3390/antib13010022>
12. Huo, R., Yang, Y., Wei, C., Huo, X., Meng, D., Yang, Y. ... Huang, X. (2025). Vitamin D affects antiphospholipid syndrome by regulating T cells (Review). *International Journal of Molecular Medicine*, 55, 30. <https://doi.org/10.3892/ijmm.2024.5471>